Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 1/20 | 0.51 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.51 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16902654 | 0.89 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL15714287 | 0.84 | TSHR (0.68) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL16905806 | 0.81 | KDM4E (0.65) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL15714138 | 0.81 | TSHR (0.73) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL4346565 | 0.80 | ALDH1A1 (0.67) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL17179761 | 0.80 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL4334060 | 0.80 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL17179775 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 | |
| SCHEMBL1885241 | 0.76 | KDM4E (1.00) | SMN1; SMN2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL15714263 | 0.76 | KDM4E (0.58) | SMN1; SMN2KDM4EALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-8552018-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552018-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110212929-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2011-09-01 | — | — | US | disclosed |
| US-20110212929-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2011-09-01 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1678166-A2 | PROTEIN KINASE INHIBITORS | Arizona Board of Regents on behalf of The University of Arizona (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050277658-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050239794-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050239793-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227992-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005037825-A2 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227992-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
| US-20050277658-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
| US-20050239794-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
| US-20050239793-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
| US-20110212929-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | SMN1; SMN2 3186/4885KDM4E 1499/4885ALDH1A1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.